High-potency cannabis fuels state debates over psychosis and addiction risks
Connecticut mother Amy Wadsworth describes how her son’s use of high-THC cannabis led to severe psychosis, addiction, and years of hospitalization, raising concerns about the mental health risks of legalized high-potency marijuana. States like Connecticut are now debating stricter THC caps amid conflicting research, industry opposition, and federal reclassification of cannabis as less restrictive.
Amy Wadsworth’s son, once a healthy teenager, began using cannabis in college to manage social anxiety and sleep issues. Within months, he experienced psychotic episodes and developed severe cannabis use disorder, derailing his life and requiring years of treatment across the U.S. Now 25, he remains trapped in a cycle of hospitals and recovery programs, with Wadsworth warning that high-THC products caused irreversible harm. Research increasingly links frequent use of high-potency cannabis—often exceeding 15% to 20% THC in flower or over 80% in concentrates—to higher risks of addiction, psychosis, and mental health decline, especially among adolescents. About 15% of Americans aged 12+ reported recent marijuana use in 2024, with roughly 30% of users developing cannabis use disorder, according to federal health agencies. Public perceptions of marijuana as harmless may be worsening as states legalize it, despite rising potency levels. States are divided over regulation. Connecticut reinstated a 35% THC cap on flower this year after initially eliminating it, citing public health concerns, though lawmakers also expanded the market for concentrates and edibles. Similar debates are unfolding in California and other states, where the cannabis industry and lawmakers clash over how far governments should intervene in a legalized market. Federal reclassification of cannabis as Schedule III in 2024 further complicates efforts to address risks, as experts argue the move downplays dangers. Dr. Alta DeRoo, chief medical officer at Hazelden Betty Ford Foundation, criticized the federal shift, stating it undermines public awareness of cannabis risks. She emphasized that potency limits are critical to preventing addiction and psychosis, particularly among vulnerable groups. Meanwhile, industry groups argue that strict regulations stifle innovation and consumer choice, leaving states to balance health warnings with economic incentives. The debate highlights a broader disconnect between scientific evidence and policy. While some states push for stricter limits, others prioritize market growth, leaving millions exposed to increasingly potent products. Wadsworth’s son’s story underscores the human cost of unchecked access, as families and researchers urge lawmakers to act before harm worsens.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.